Yield10 Bioscience Inc
NASDAQ:YTEN
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Yield10 Bioscience Inc
NASDAQ:YTEN
|
3.5m USD | 0 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 8.9 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 10.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.1 | ||
AU |
CSL Ltd
ASX:CSL
|
133B AUD | 13.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 17.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 5 | ||
KR |
Celltrion Inc
KRX:068270
|
38.9T KRW | 37.9 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.